首页 › 期刊 › 医学 › Cancer Research and Treatment
Cancer Research and Treatment
出版商:Korean Cancer Association · ISSN:1598-2998, 2005-9256 · 国家/地区:KR · 类型:journal · OA 开放获取 · 官网:https://www.e-crt.org
研究主题:Lung Cancer Treatments and Mutations · Lung Cancer Diagnosis and Treatment · Gastric Cancer Management and Outcomes · Breast Cancer Treatment Studies · Lung Cancer Research Studies
数据覆盖:9 个公开学术数据源交叉核验(crossref、fqb、jcr、openalex、scimago、wikidata、xr、cwts、jufo)。
数据来源与实体核验
期刊官网 · OpenAlex 期刊实体 · Wikidata 期刊实体
核心指标
- 影响因子(JCR 2025):4.200
- JCR 分区:Q2(ONCOLOGY)
- 中科院分区(2025):医学 2区,大类排名 898/5603;小类:ONCOLOGY 肿瘤学 3区,排名 81/318
- 新锐分区(2026):医学 3区
- SJR:1.462(Q1),2025 年,South Korea
- CWTS 2025:SNIP 1.354 · IPP 4.249 · 自引率 1.6%
- JUFO 出版渠道等级:芬兰 1 · 挪威 1
- h-index:85
- i10 指数:1267
- 近两年篇均被引:3.13
- 载文量 2350 · 总被引 51959
- Crossref DOI 总量:2349,近期 438
逐年趋势
- 近年影响因子:2020 4.68 → 2021 5.04 → 2022 4.6 → 2023 4.1 → 2024 3.8
- 近年 SJR:2021 1.36(Q1) → 2022 1.34(Q1) → 2023 1.25(Q1) → 2024 1.43(Q1) → 2025 1.46(Q1)
同学科期刊推荐
- CA-A CANCER JOURNAL FOR CLINICIANS — IF 685.2 · JCR Q1 · 中科院1区(Top)
- The Lancet — IF 109.0 · JCR Q1 · 中科院1区(Top)
- MMWR Surveillance Summaries — IF 96.9 · JCR Q1 · 中科院1区(Top)
- Nature Reviews Clinical Oncology — IF 94.6 · JCR Q1 · 中科院1区(Top)
- Nature Reviews Drug Discovery — IF 91.2 · JCR Q1 · 中科院1区(Top)
- New England Journal of Medicine — IF 84.5 · JCR Q1 · 中科院1区(Top)
- Signal Transduction and Targeted Therapy — IF 81.2 · JCR Q1 · 中科院1区(Top)
- Annals of Oncology — IF 80.4 · JCR Q1 · 中科院1区(Top)
常见问题
《Cancer Research and Treatment》的影响因子是多少?
根据 JCR 2025 年数据,《Cancer Research and Treatment》的最新影响因子(IF)为 4.200。
《Cancer Research and Treatment》是几区期刊?
《Cancer Research and Treatment》中科院分区(2025年版)为医学2区,JCR 分区为 Q2。
《Cancer Research and Treatment》是开放获取(OA)期刊吗?
是,《Cancer Research and Treatment》是开放获取(Open Access)期刊。
本刊近期代表论文
- Early On-Treatment Host Fitness Dynamics Refine Prognostic Stratification in Advanced NSCLC Receiving First-Line Immunotherapy (2026)
- Nivolumab Plus Chemotherapy versus Placebo Plus Chemotherapy in Korean Patients with HER2-Negative, Untreated, Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer: Subgroup Analysis of a Randomized, Multicenter, Double-Blind Phase 3 Trial (ATTRACTION-4) (2025 · 被引 3)
- Recent Advances in Genomic Approaches for the Detection of Homologous Recombination Deficiency (2024 · 被引 10)
- Application of Machine Learning Algorithms for Risk Stratification and Efficacy Evaluation in Cervical Cancer Screening among the ASCUS/LSIL Population: Evidence from the Korean HPV Cohort Study (2024 · 被引 9)
- Impact of TTF-1 Expression on the Prognostic Prediction of Patients with Non–Small Cell Lung Cancer with PD-L1 Expression Levels of 1% to 49%, Treated with Chemotherapy vs. Chemoimmunotherapy: A Multicenter, Retrospective Study (2024 · 被引 7)
- A Single-Arm Phase II Study of Nab-Paclitaxel Plus Gemcitabine and Cisplatin for Locally Advanced or Metastatic Biliary Tract Cancer (2023 · 被引 7)